The Use of Heparin during Endovascular Peripheral Arterial Interventions: A Synopsis

Arno M Wiersema, Christopher Watts, Alexandra C Durran, Michel M P J Reijnen, Otto M van Delden, Frans L Moll, Jan Albert Vos, Arno M Wiersema, Christopher Watts, Alexandra C Durran, Michel M P J Reijnen, Otto M van Delden, Frans L Moll, Jan Albert Vos

Abstract

A large variety exists for many aspects of the use of heparin as periprocedural prophylactic antithrombotics (PPAT) during peripheral arterial interventions (PAI). This variation is present, not only within countries, but also between them. Due to a lack of (robust) data, no systematic review on the use of heparin during PAI could be justified. A synopsis of all available literature on heparin during PAI describes that heparin is used on technical equipment to reduce the thrombogenicity and in the flushing solution with saline. Heparin could have a cumulative anticoagulant effect when used in combination with ionic contrast medium. No level-1 evidence exists on the use of heparin. A measurement of actual anticoagulation status by means of an activated clotting time should be mandatory.

References

    1. Durran A. C., Watts C. Current trends in heparin use during arterial vascular interventional radiology. CardioVascular and Interventional Radiology. 2012;35(6):1308–1314. doi: 10.1007/s00270-011-0337-1.
    1. Wiersema A. M., Vos J.-A., Bruijninckx C. M. A., et al. Periprocedural prophylactic antithrombotic strategies in interventional radiology: current practice in the netherlands and comparison with the United Kingdom. CardioVascular and Interventional Radiology. 2013;36(6):1477–1492. doi: 10.1007/s00270-013-0558-6.
    1. Miller D. L. Heparin in angiography: current patterns of use. Radiology. 1989;172(3, part 2):1007–1011. doi: 10.1148/172.3.1007.
    1. Jackson D. M. A., Dawson P. Current usage of contrast agents, anticoagulant and antiplatelet drugs in angiography and angioplasty in the UK. Clinical Radiology. 1995;50(10):699–704. doi: 10.1016/S0009-9260(05)83316-1.
    1. Zaman S. M., De Vroos Meiring P., Gandhi M. R., Gaines P. A. The pharmacokinetics and UK usage of heparin in vascular intervention. Clinical Radiology. 1996;51(2):113–116. doi: 10.1016/S0009-9260(96)80267-4.
    1. Prechel M., Walenga J. M. Heparin-induced thrombocytopenia: an update. Seminars in Thrombosis and Hemostasis. 2012;38(5):483–496. doi: 10.1055/s-0032-1306432.
    1. De Swart C. A. M., Nijmeyer B., Roelofs J. M. M., Sixma J. J. Kinetics of intravenously administered heparin in normal humans. Blood. 1982;60(6):1251–1258.
    1. Cipolle R. J., Seifert R. D., Neilan B. A., Zaske D. E., Haus E. Heparin kinetics: variables related to disposition and dosage. Clinical Pharmacology and Therapeutics. 1981;29(3):387–393. doi: 10.1038/clpt.1981.53.
    1. Mabry C. D., Thompson B. W., Read R. C., Campbell G. S. Activated clotting time monitoring of intraoperative heparinization: our experience and comparison of two techniques. Surgery. 1981;90(5):889–895.
    1. Horton S., Augustin S. Activated clotting time (ACT) Methods in Molecular Biology. 2013;992:155–167. doi: 10.1007/978-1-62703-339-8-12.
    1. Gunnarsson U., Seligsohn E., Jestin P., Påhlman L. Registration and validity of surgical complications in colorectal cancer surgery. British Journal of Surgery. 2003;90(4):454–459. doi: 10.1002/bjs.4058.
    1. Norgren L., Hiatt W. R., Dormandy J. A., et al. Inter-society consensus for the management of peripheral arterial disease (TASC II) International Angiology. 2007;26(2):82–157.
    1. Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Standards of Practice, 2012,
    1. Wiersema A., Bruijninckx C., Reijnen M., et al. Perioperative prophylactic antithrombotic strategies in vascular surgery: current practice in the Netherlands. Journal of Cardiovascular Surgery. 2015;56(1):119–125.
    1. Wiersema A. M., Jongkind V., Bruijninckx C. M. A., et al. Prophylactic perioperative anti-thrombotics in open and endovascular Abdominal Aortic Aneurysm (AAA) surgery: a systematic review. European Journal of Vascular and Endovascular Surgery. 2012;44(4):359–367. doi: 10.1016/j.ejvs.2012.06.008.
    1. Wiersema A., Jongkind V., Bruuninckx C., et al. Prophylactic intraoperative antithrombotics in open infrainguinal arterial bypass surgery: a systematic review. Journal of Cardiovascular Surgery. 2015;56(1):127–143.
    1. Hirsh J., Warkentin T. E., Raschke R., Granger C., Ohman E. M., Dalen J. E. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1998;114(5):489s–510s.
    1. Cramer R., Frech R. S., Amplatz K. A preliminary human study with a simple nonthrombogenic catheter. Radiology. 1971;100(2):421–422. doi: 10.1148/100.2.421.
    1. Ovitt T. W., Durst S., Moore R., Amplatz K. Guide wire thrombogenicity and its reduction. Radiology. 1974;111(1):43–46. doi: 10.1148/111.1.43.
    1. Cramer R., Moore R., Amplatz K. Reduction of the surgical complication rate by the use of a hypothrombogenic catheter coating. Radiology. 1973;109(3):585–588. doi: 10.1148/109.3.585.
    1. Hawkins I. F., Jr., Kelley M. J. Benzalkonium—heparin-coated angiographic catheters. Experience with 563 patients. Radiology. 1973;109(3):589–591. doi: 10.1148/109.3.589.
    1. Kido D. K., Paulin S., Alenghat J. A., Waternaux C., Riley W. D. Thrombogenicity of heparin and non-heparin-coated catheters: clinical trial. American Journal of Roentgenology. 1982;139(5):957–961. doi: 10.2214/ajr.139.5.957.
    1. Leach K. R., Kurisu Y., Carlson J. E., et al. Thrombogenicity of hydrophilically coated guide wires and catheters. Radiology. 1990;175(3):675–677. doi: 10.1148/radiology.175.3.2343111.
    1. Lee K. H., Han J. K., Byun Y., et al. Heparin-coated angiographic catheters: an in vivo comparison of three coating methods with different heparin release profiles. CardioVascular and Interventional Radiology. 2004;27(5):507–511. doi: 10.1007/s00270-003-4035-5.
    1. Bittl J. A. Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis. Journal of Cardiovascular Pharmacological Therapy. 2005;10(4):209–216.
    1. Stamler S., Katzen B. T., Tsoukas A. I., Baum S. Z., Diehm N. Clinical experience with the use of bivalirudin in a large population undergoing endovascular abdominal aortic aneurysm repair. Journal of Vascular Interventional Radiology. 2009;20:17–21.
    1. Dumaine R., Borentain M., Bertel O., et al. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention. Archives of Internal Medicine. 2007;167(22):2423–2430.
    1. Diez J. G. Practical issues on the use of enoxaparin in elective and emergent percutaneous coronary intervention. Journal of Invasive Cardiology. 2008;20(9):482–489.
    1. Duschek N., Vafaie M., Skrinjar E., et al. Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial. Journal of Thrombosis and Haemostasis. 2011;9(11):2159–2167.
    1. Walker S., Beasley C., Reeves M. A retrospective study on the use of heparin for peripheral vascular intervention. Perspectives of Vascular Surgery and Endovascular Therapy. 2012;24(263):269.
    1. Grainger R. G. Intravascular contrast media—the past, the present and the future. British Journal of Radiology. 1982;55(649):1–18. doi: 10.1259/0007-1285-55-649-1.
    1. Ing J. J., Smith D. C., Bull B. S. Differing mechanisms of clotting inhibition by ionic and nonionic contrast agents. Radiology. 1989;172(2):345–348. doi: 10.1148/radiology.172.2.2748812.
    1. Piessens J. H., Stammen F., Vrolix M. C., et al. Effects of an ionic versus a nonionic low osmolar contrast agent on the thrombotic complications of coronary angioplasty. Catheterization and Cardiovascular Diagnosis. 1993;28(2):99–105. doi: 10.1002/ccd.1810280203.
    1. Casalini E. Role of low-osmolality contrast media in thromboembolic complications: scanning electron microscopy study. Radiology. 1992;183(3):741–744. doi: 10.1148/radiology.183.3.1584930.
    1. Parvez Z., Moncada R. Nonionic contrast medium: effects on blood coagulation and complement activation in vitro. Angiology. 1986;37(5):358–364. doi: 10.1177/000331978603700504.
    1. Raininko R., Riihelä M. Blood clot formation in angiographic catheters. In vitro tests with various contrast media. Acta Radiologica. 1990;31(2):217–220. doi: 10.3109/02841859009177492.
    1. Nejad M. S., Klaper M. A., Steggerda F. R., Gianturco C. Clotting on the outer surfaces of vascular catheters. Radiology. 1968;91(2):248–250. doi: 10.1148/91.2.248.
    1. Anderson J. H., Gianturco C., Wallace S., Dodd G. D., DeJongh D. Anticoagulation techniques for angiography. An experimental study. Radiology. 1974;111(3):573–576. doi: 10.1148/111.3.573.
    1. Dawson P., Cousins C., Bradshaw A. The clotting issue: etiologic factors in thromboembolism: II. clinical considerations. Investigative Radiology. 1993;28(supplement 5):S31–S38. doi: 10.1097/00004424-199308003-00016.
    1. Scott J. A., Berenstein A., Blumenthal D. Use of the activated coagulation time as a measure of anticoagulation during interventional procedures. Radiology. 1986;158(3):849–850. doi: 10.1148/radiology.158.3.3945764.
    1. Chew D. P., Bhatt D. L., Lincoff A. M., et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. 2001;103(7):961–966. doi: 10.1161/01.cir.103.7.961.
    1. Kasapis C., Gurm H. S., Chetcuti S. J., et al. Defining the optimal degree of heparin anticoagulation for peripheral vascular interventions insight from a large, regional, multicenter registry. Circulation: Cardiovascular Interventions. 2010;3(6):593–601. doi: 10.1161/CIRCINTERVENTIONS.110.957381.
    1. Vacek J. L., Hibiya K., Rosamond T. L., Kramer P. H., Beauchamp G. D. Validation of a bedside method of activated partial thromboplastin time measurement with clinical range guidelines. The American Journal of Cardiology. 1991;68(5):557–559. doi: 10.1016/0002-9149(91)90800-Z.
    1. Dougherty K. G., Gaos C. M., Bush H. S., Leachman D. R., Ferguson J. J. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Catheterization and Cardiovascular Diagnosis. 1992;26(4):260–263. doi: 10.1002/ccd.1810260404.
    1. Klein L. W., Agarwal J. B. When we “act” on ACT levels: activated clotting time measurements to guide heparin administration during and after interventional procedures. Catheterization and Cardiovascular Diagnosis. 1996;37:154–157.
    1. Carr J. A., Silverman N. The heparin-protamine interaction. A review. Journal of Cardiovascular Surgery. 1999;40(5):659–666.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere